Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma

Doorduijn, J.K., van der Holt, B., van Imhoff, G.W., van der Hem, K.G., Kramer, M.H.H., van Oers, M.H.J., Ossenkoppele, G.J., Schaafsma, M.R., Verdonck, L.F., Verhoef, G.E.G., Steijaert, M.M.C., Buijt, I., Uyl-de Groot, C.A., van Agthoven, M., Mulder, A.H., Sonneveld, P.·2003·Journal of Clinical Oncology

Abstract

Purpose: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin’s lymphoma (NHL). Patients and Methods: Patients aged 65 to 90 years (median, 72 years) with stage II to IV aggressive NHL were randomly assigned to receive standard CHOP every 3 weeks or CHOP plus G-CSF every 3 weeks on days 2 to 11 of each cycle. Results: In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P = .01) and doxorubicin (median, 95.4% v 93.3%; P = .04) were higher in patients treated with CHOP plus G-CSF. The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P = .63). The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P = .76), with a median follow-up of 33 months. Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles). Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P = .006) than with CHOP alone. The number of hospital admissions and the number of days in hospital were not different. Conclusion: In elderly patients, G-CSF improved the RDI of CHOP, but this did not lead to a higher complete response rate or better overall survival. G-CSF did not prevent serious infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2003.01.076

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 168

Metadata

Authors
Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H. H., van Oers, M. H. J., Ossenkoppele, G. J., Schaafsma, M. R., Verdonck, L. F., Verhoef, G. E. G., Steijaert, M. M. C., Buijt, I., Uyl-de Groot, C. A., van Agthoven, M., Mulder, A. H., & Sonneveld, P.
Venue
Journal of Clinical Oncology
Published
2003-08-15
Volume
21
Issue
16
Pages
3041-3050
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2133120925
Cited by
168
References
2
FWCI
8.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2003.01.076
The paper
Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H. H., van Oers, M. H. J., Ossenkoppele, G. J., Schaafsma, M. R., Verdonck, L. F., Verhoef, G. E. G., Steijaert, M. M. C., Buijt, I., Uyl-de Groot, C. A., van Agthoven, M., Mulder, A. H., & Sonneveld, P. (2003). CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.01.076

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.